Nuvectis Pharma Inc (NVCT) Stock Price, Quote & News

Company Profile

Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis...

Industry: Biotechnology

Sector: Healthcare

Phone: 201 614 3150

Website: www.nuvectis.com

Address:

1 Bridge Plaza, 2nd Floor, Suite 275, Fort Lee, United States

UNLV Apr. 10 at 1:53 PM

$NVCT December company will have 1 year data around Tagrisso combo and other resistance targets. 2027 brings ATH 20+ and maybe far beyond with mono therapies as free-rolls. Short term price movements just entertainment, more like chatter and noise imo

0 · Reply

buyandsold Apr. 8 at 2:45 PM

$NVCT the climb to 9 Again

1 · Reply

BioTrade2 Apr. 6 at 8:09 PM

$NVCT 900 monotherapy arm started enrolling patients last Aug/Sep and still no updates. 12 sites! All hopes on combo arm now? Ron said combo data update mid year, 3 sites. Make it make sense.

2 · Reply

UNLV Apr. 2 at 2:14 PM

$NVCT PT $35 minimum - huge insider holdings aren’t after 2x or 3x gains NOTHING else matters, daily-weekly-monthly movements are nothing but noise and chatter from those with little to no conviction

0 · Reply

UNLV Mar. 31 at 5:29 PM

$NVCT often times there’re challenges recruiting patients around bio marker led clinical trials. Assuming this after seeing abstracts for upcoming April presentation PT $35 minimum - insiders aren’t going after 2x or 3x possibilities

0 · Reply

WallStWireAds Mar. 31 at 12:02 PM

$NVCT https://www.globenewswire.com/news-release/2026/03/31/3265375/0/en/Nuvectis-Pharma-Announces-Upcoming-Presentations-for-NXP900-at-the

0 · Reply

UNLV Mar. 30 at 6:48 PM

$NVCT added a little more at my highest buy price, averaging up not down. So many possibilities 1b

1 · Reply

buyandsold Mar. 30 at 5:32 PM

$NVCT a nasty month.

0 · Reply

buyandsold Mar. 28 at 3:02 AM

$NVCT i bought more today, it is going to be zero or $100. in reality i could not hold to $100 as I would trim all the way up

0 · Reply

BioTrade2 Mar. 25 at 6:23 PM

$NVCT that tern chart, 25 bagger in under 1 year!

1 · Reply

Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting

Feb 11, 2026, 7:30 AM EST - 2 months ago

Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights

Dec 17, 2025, 7:00 AM EST - 4 months ago

Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC

Nov 25, 2025, 8:00 AM EST - 5 months ago

Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC

Nov 4, 2025, 8:15 AM EST - 5 months ago

CORRECTION: Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights

Oct 16, 2025, 8:00 AM EDT - 6 months ago

Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Sep 4, 2025, 7:30 AM EDT - 7 months ago

Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 11, 2025, 4:30 PM EDT - 8 months ago

Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900

Aug 5, 2025, 7:30 AM EDT - 9 months ago

Nuvectis Pharma, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights

Jul 31, 2025, 7:45 AM EDT - 9 months ago

Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation Study

May 16, 2025, 4:35 PM EDT - 11 months ago

Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference

May 6, 2025, 8:00 AM EDT - 1 year ago

Nuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights

Apr 29, 2025, 4:25 PM EDT - 1 year ago

Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR Meeting

Mar 14, 2025, 8:00 AM EDT - 1 year ago

Nuvectis Pharma to Participate in the 37th Annual Roth Conference

Feb 7, 2025, 8:30 AM EST - 1 year ago

Nuvectis Pharma Announces Closing of $15.5 Million Public Offering of Common Stock and Full Exercise of Underwriter's Over-Allotment Option

Feb 5, 2025, 9:01 AM EST - 1 year ago

Nuvectis Pharma Announces Pricing of $13.5 Million Public Offering of Common Stock

Feb 4, 2025, 4:05 PM EST - 1 year ago

Nuvectis Pharma Announces Proposed Public Offering of Common Stock

Nov 14, 2024, 2:23 PM EST - 1 year ago

Nuvectis Pharma CEO Says Increased Dose Intensity Needed To Drive More Efficacy From Ovarian Cancer Lead Drug

Nov 5, 2024, 7:00 AM EST - 1 year ago

Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights

Oct 28, 2024, 8:21 AM EDT - 1 year ago

PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update

DRUG

Aug 29, 2024, 8:00 AM EDT - 1 year ago

Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA for NXP800 for the Treatment of ARID1a-deficient Ovarian, Fallopian Tube, and Primary Peritoneal Cancers

Aug 6, 2024, 8:28 AM EDT - 1 year ago

Nuvectis Pharma, Inc. Reports Second Quarter 2024 Financial Results and Business Highlights

May 16, 2024, 8:30 AM EDT - 2 years ago

Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference

May 7, 2024, 8:00 AM EDT - 2 years ago

Nuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and Business Highlights

Apr 8, 2024, 8:30 AM EDT - 2 years ago

Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines

Mar 19, 2024, 8:00 AM EDT - 2 years ago

Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meeting

Mar 15, 2024, 8:00 AM EDT - 2 years ago

Nuvectis Pharma to Present at the 36th Annual Roth Conference

Mar 14, 2024, 9:00 AM EDT - 2 years ago

Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer

Mar 5, 2024, 8:00 AM EST - 2 years ago

Nuvectis Pharma, Inc. Reports Fiscal Year 2023 Financial Results and Business Highlights

Feb 9, 2024, 8:32 AM EST - 2 years ago

Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences

Feb 9, 2024, 8:00 AM EST - 2 years ago

Nuvectis Pharma Announces Participation at Upcoming Investor Conferences

Jan 3, 2024, 8:00 AM EST - 2 years ago

Nuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Nov 8, 2023, 8:00 AM EST - 2 years ago

Nuvectis Pharma, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights

Sep 25, 2023, 7:30 PM EDT - 2 years ago

Nuvectis Pharma Announces Updated Date and Time for the 2023 Cantor Global Healthcare Conference Corporate Presentation

Sep 21, 2023, 8:00 AM EDT - 2 years ago

Nuvectis Pharma Announces Upcoming Presentations for NXP800 and NXP900

Sep 6, 2023, 8:00 AM EDT - 2 years ago

Nuvectis Pharma to Host KOL Event to Discuss Its Two Precision Medicine Clinical-Stage Drug Candidates, NXP800 and NXP900

Aug 17, 2023, 8:00 AM EDT - 2 years ago

Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA to NXP800 for the Treatment of Cholangiocarcinoma

Aug 9, 2023, 8:00 AM EDT - 2 years ago

Nuvectis Pharma, Inc. Reports Second Quarter 2023 Financial Results and Business Highlights

May 15, 2023, 8:00 AM EDT - 3 years ago

Nuvectis Pharma Announces FDA Clearance of NXP900 IND

May 10, 2023, 8:00 AM EDT - 3 years ago

Nuvectis Pharma, Inc. Reports First Quarter 2023 Financial Results and Business Highlights

Apr 27, 2023, 10:14 AM EDT - 3 years ago

Correction: Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference

Apr 10, 2023, 8:00 AM EDT - 3 years ago

Nuvectis Pharma Announces Initiation of the Phase 1b Study for NXP800 in Platinum-Resistant, ARID1a-Mutated Ovarian Carcinoma

Mar 17, 2023, 8:00 AM EDT - 3 years ago

Nuvectis Pharma Announces Upcoming Presentations at the 2023 American Association for Cancer Research Meeting

Mar 10, 2023, 8:00 AM EST - 3 years ago

Nuvectis Pharma to Participate in a Fireside Chat at the 35th Annual Roth Conference

Mar 7, 2023, 8:00 AM EST - 3 years ago

Nuvectis Pharma, Inc. Reports Fiscal Year 2022 Financial Results and Business Highlights

Dec 1, 2022, 8:00 AM EST - 3 years ago

FDA Grants Fast Track Designation to Nuvectis Pharma's NXP800 for the Treatment of Platinum-Resistant, ARID1A-Mutated Ovarian Carcinoma

Nov 8, 2022, 8:00 AM EST - 3 years ago

Nuvectis Pharma, Inc. Reports Third Quarter 2022 Financial Results and Business Highlights

Oct 18, 2022, 8:00 AM EDT - 3 years ago

Nuvectis Phrama Announces Two Upcoming Poster Presentations at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

UNLV Apr. 10 at 1:53 PM

0 · Reply

buyandsold Apr. 8 at 2:45 PM

$NVCT the climb to 9 Again

1 · Reply

BioTrade2 Apr. 6 at 8:09 PM

$NVCT 900 monotherapy arm started enrolling patients last Aug/Sep and still no updates. 12 sites! All hopes on combo arm now? Ron said combo data update mid year, 3 sites. Make it make sense.

2 · Reply

UNLV Apr. 2 at 2:14 PM

0 · Reply

UNLV Mar. 31 at 5:29 PM

0 · Reply

WallStWireAds Mar. 31 at 12:02 PM

$NVCT https://www.globenewswire.com/news-release/2026/03/31/3265375/0/en/Nuvectis-Pharma-Announces-Upcoming-Presentations-for-NXP900-at-the

0 · Reply

UNLV Mar. 30 at 6:48 PM

$NVCT added a little more at my highest buy price, averaging up not down. So many possibilities 1b

1 · Reply

buyandsold Mar. 30 at 5:32 PM

$NVCT a nasty month.

0 · Reply

buyandsold Mar. 28 at 3:02 AM

$NVCT i bought more today, it is going to be zero or $100. in reality i could not hold to $100 as I would trim all the way up

0 · Reply

BioTrade2 Mar. 25 at 6:23 PM

$NVCT that tern chart, 25 bagger in under 1 year!

1 · Reply

essiepaul Mar. 19 at 2:42 PM

$NVCT back to reality with this hound

0 · Reply

OfficialStocktwitsUser Mar. 18 at 10:35 PM

$NVCT RSI: 38.54, MACD: 0.0506 Vol: 0.32, MA20: 8.89, MA50: 8.69 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

BioTrade2 Mar. 18 at 2:33 AM

$NVCT what to look for over the next few months. 1) If they raise before or after the data? 2) using ATM again? (Vol/price action over the past few days makes very little sense) 3) Announce if any of the monotherapy cohorts reaches full enrollment 4) next time we hear from them, any conferences or quarterly calls?

1 · Reply

KingMillion25 Mar. 17 at 10:44 AM

$NVCT Q2 data incoming

0 · Reply

LawrenceStevenson1996 Mar. 10 at 5:32 PM

$NVCT Small cap health. Quiet session.

0 · Reply

biospeculator Mar. 10 at 4:12 PM

$NVCT Massive inverse head & shoulders pattern building with a $11 neckline and a target of $18-$20 imo. GLTA

0 · Reply

Elgallo353 Mar. 10 at 3:43 PM

$NVCT why the increase ? any other forum where there is more info ? this is so quiet…

1 · Reply

UNLV Feb. 27 at 2:27 PM

$NVCT phase 1b moving forward and SecForm4 shows ZERO insider selling. Charles Mosseri Marlio doesn’t work for Nuvectis and isn’t strictly bound by insider trading rules. Piggybacked his huge buys around friendship with CEO unless and until he starts selling have to believe positives around 1b @BioTrade2 and there’s nothing better than getting in huge at ground floor

1 · Reply

StocktwitsEarnings Feb. 25 at 3:30 PM

$NVCT Q4 '25 Earnings Results & Recap Nuvectis Pharma reported a net loss of $(26,442) thousand and basic net loss per share of $(1.32) for FY2025, with $31,634 thousand in cash. Nuvectis Pharma ceased NXP800 development and initiated NXP900 Phase 1b expansion in 2025.

0 · Reply

OfficialStocktwitsUser Feb. 22 at 7:05 PM

$NVCT RSI: 58.37, MACD: 0.1273 Vol: 0.23, MA20: 8.60, MA50: 8.26 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

BillionerOfKing Feb. 18 at 4:21 PM

$NVCT Current Stock Price: $8.91 Contracts to trade: $7.5 NVCT Feb 20 2026 Call Entry: $0.35 Exit: $0.60 ROI: 72% Hold ~31 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

UNLV Feb. 17 at 6:28 PM

$NVCT IMO upcoming data around the big target of tagrisso resistance will propel stock price setting up a “FREE-ROLL on ALL other indications”. Keeping patients on tagrisso an additional 6 months or longer would be welcomed by medical professionals and catapult company to profitability

0 · Reply

Market Cap	224.12M
Revenue (ttm)	0.00
Net Income (ttm)	-26.44M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	46,400
Avg Vol	57,962
Day's Range	N/A - N/A
Shares Out	26.49M
Stochastic %K	90%
Beta	-0.21
Analysts	Strong Sell
Price Target	$18.00